FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology. Disclosed are nucleic acid molecules containing one or more nucleic acid sequences that encode a modified MUC16 consensus antigen. Described are vectors, compositions and vaccines containing one or more nucleic acid sequences that encode a modified MUC16 consensus antigen. Methods of treating a subject with a tumor expressing MUC16 and methods of preventing a tumor expressing MUC16 are disclosed. A modified MUC16 consensus antigen is disclosed.
EFFECT: invention ensures the production of safe and effective vaccines that are applicable to tumors expressing MUC16, thereby providing treatment and promoting the survival of individuals affected by such cancers.
27 cl, 54 dwg, 28 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| MUC16-TARGETING ANTICANCER VACCINES AND APPLICATION THEREOF | 2018 |
|
RU2777918C2 |
| MESOTHELINE-TARGETED CANCER VACCINES AND THEIR APPLICATION | 2018 |
|
RU2751252C1 |
| IMMUNOGENS FOR VACCINATION AGAINST HIV | 2013 |
|
RU2721274C2 |
| ANTIBODIES TO MUC16 AND THEIR APPLICATION | 2016 |
|
RU2758113C2 |
| AFRICAN SWINE FEVER VACCINE | 2020 |
|
RU2819672C2 |
| ISOLATED RECOMBINANT VIRUS BASED ON INFLUENZA VIRUS FOR INDUCING SPECIFIC IMMUNITY TO INFLUENZA VIRUS AND/OR PREVENTING DISEASES CAUSED BY INFLUENZA VIRUS | 2021 |
|
RU2813150C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
| VACCINE COMPOSITION AGAINST INFECTION CAUSED BY STREPTOCOCCUS SUIS | 2015 |
|
RU2735101C2 |
| VACCINE COMPOSITION FOR TREATMENT OF CANCER | 2018 |
|
RU2782261C2 |
| ANTI-CANCER VACCINES AIMED AT LEMD1 AND THEIR USE | 2018 |
|
RU2760984C1 |
